When the commercial thesis is tested, it holds.
Investor- and partner-grade commercial analysis for pre-commercial frontier science companies. Fixed-scope projects. Board-ready deliverables.
The commercial bar for early-stage life sciences companies has kept rising. Lead co-investors and pharma partnering counterparties apply sharper commercial scrutiny earlier — on indication rationale, market framing, competitive positioning — than they did even a few years ago.
Companies whose upstream commercial decisions were engineered against today's bar raise and partner from strength. Companies whose commercial story comes together late spend more time in diligence, accept dilutive terms, or see the counterparty's internal assessment set the frame.
An investor opens the commercial section of the deck. The market sizing is constructed around the variables they probe. The indication rationale addresses the commercial criteria they apply. The commercial narrative is specific to the mechanism. The board meeting has a deliverable on the table — transparent methodology the board can interrogate.
Named deliverables the CEO presents to the board. The same analytical architecture, applied each time to the company's specific commercial position.
- Commercial Position Diagnostic
- Where the commercial thesis stands, where it's exposed, and what the next evaluation will target. Two weeks. Board-ready. A fixed-scope on-ramp.
- Components
- Standalone deliverables on a specific commercial question. Indication prioritization. Market re-assessment. Competitive landscape. Each scoped and priced individually.
- Sprints
- Integrated packages that combine multiple components into a single engagement. A Series B commercial narrative. A partnering-readiness assessment. Fixed scope, fixed timeline.
- Retained support
- For companies where commercial questions are continuous rather than triggered. Monthly engagement, still artifact-producing — every month closes with a deliverable, not a time sheet.
Every deliverable is designed so the CEO can present it to the board without edits and without an outside advisor in the room.
The upstream decisions are built against the downstream evaluation.
The market framing, indication rationale, and commercial narrative in every deliverable are engineered against the specific evaluations a co-investor, partner, or acquirer runs on pre-commercial companies in this modality. The pattern for which upstream decisions hold up under that scrutiny comes from 15+ years of senior healthcare commercial strategy and business development, including at the largest healthcare-dedicated agency network — the single seat that sees the lion's share of pharma and biotech commercialization and launch RFPs, among the work pharma externalizes to agency-network commercial groups specifically.
The numbers and framings are stress-tested before you see them.
The analytical architecture uses designed LLM-based workflows built at enterprise scale specifically for commercial strategy — producing adversarial multi-pass critique, source-grounded reasoning, and systematic sensitivity analysis on every conclusion. A categorically different kind of analytical process. The commercial section you present to the board has been challenged from multiple angles before it arrives on your desk.
Each commercial call is evaluated against the lens your next counterparty will apply.
The same kind of proactive commercial-potential evaluation a VC's own scouting function runs, turned on the portfolio company's own upstream decisions. When the indication is chosen, when the market framing is set — each call is evaluated against the criteria the next investor or partner will use to decide whether to lean in.
Pre-commercial frontier science companies approaching a live commercial trigger.
- 15+ years of senior healthcare commercial strategy and business development, including at the largest healthcare-dedicated agency network
- Extensive market opportunity and in-licensing assessment across pharma and biotech
- Leader in AI-augmented analytical workflows
The first engagement is typically a Commercial Position Diagnostic: two weeks, board-ready deliverable at the end.
Small enough to evaluate the work on its merits before any further commitment.